Besides CLL, breast cancer, and cholangiocarcinoma, considering the numerous human tumors that overexpress this gene [19], it is very likely that RRAS2 overactivation through dose amplification will be implicated in many other cancers with significant impacts on human health. This evidence concerns the gene RRAS2 and breast carcinoma.